No black box warning on record for Sumansetron

As of the latest FDA labeling reviewed, Sumansetron (SUMATRIPTAN SUCCINATE, ONDANSETRON) does not carry a black box warning. Standard warnings and precautions still apply — see the full Sumansetron medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions including anaphylaxis and bronchospasm: Discontinue ondansetron tablets if suspected. Monitor and treat promptly per standard of care until signs and symptoms resolve ( 5.1 ) QT interval prolongation and Torsade de Pointes: Avoid in patients with congenital long QT syndrome; monitor with electrocardiograms (ECGs) if concomitant electrolyte abno

No black box warning on record for Sumansetron

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions including anaphylaxis and bronchospasm: Discontinue ondansetron tablets if suspected. Monitor and treat promptly per standard of care until signs and symptoms resolve ( 5.1 ) QT interval prolongation and Torsade de Pointes: Avoid in patients with congenital long QT syndrome; monitor with electrocardiograms (ECGs) if concomitant electrolyte abno

Sumansetron Black Box Warning

No black box warning on record for Sumansetron

Other warnings & precautions

Sumansetron Black Box Warning

No black box warning on record for Sumansetron

Other warnings & precautions